Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
3
result(s) for
"Novackova, Markéta"
Sort by:
Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study
by
Lazarák, Tomáš
,
Nováčková, Markéta
,
Varvařovský, Ivo
in
Absorbable Implants
,
Acute Coronary Syndrome - diagnostic imaging
,
Acute Coronary Syndrome - therapy
2022
Background
Magnesium-based bioresorbable Magmaris stents are rapidly resorbed. Few randomized studies have evaluated the efficacy of such stents in patients with acute coronary syndrome.
Aim
To investigate late lumen loss as assessed via quantitative coronary angiography (QCA) and optical coherence tomography (OCT) in patients with acute coronary syndrome treated with Magmaris stents or permanent, everolimus-eluting metallic Xience stents.
Methods and Results
This PRAGUE-22 study was a two-centre, investigator-initiated, randomized study. Fifty patients were randomized based on the inclusion criteria for acute coronary syndrome and the anatomical suitability to receive Magmaris or Xience stents. The patient characteristics did not differ between the Magmaris group (
n
= 25) and Xience group (
n
= 25). The mean ages were 57.0 ± 10.5 vs. 55.5 ± 9.2 years (
p
= 0.541) and the total implanted stent length was 24.6 ± 10.7 mm vs. 27.6 ± 11.1 mm (
p
= 0.368), respectively. Four clinical events occurred in the Magmaris group and one in the Xience group during 12 months of follow-up. The extent of late lumen loss (assessed via QCA) at 12 months was greater in the Magmaris group than in the Xience group (0.54 ± 0.70 vs. 0.11 ± 0.37 mm;
p
= 0.029). The late lumen loss diameter (measured via OCT) in the Magmaris group was also significantly larger than that in the Xience group (0.59 ± 0.37 vs. 0.22 ± 0.20 mm;
p
= 0.01).
Conclusion
Implantation of a magnesium-based bioresorbable stent in patients with acute coronary syndrome is associated with a greater extent of late lumen loss at the 12-month follow-up compared with implantation of a permanent, everolimus-eluting metallic stent.
Trial Registration:
ISRCTN89434356
Journal Article
Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic
by
Motovska, Zuzana
,
Kroupa, Josef
,
Toušek, Petr
in
Acute coronary syndromes
,
Algorithms
,
Clinical medicine
2020
The COVID-19 pandemic presents several challenges for managing patients with acute coronary syndrome (ACS). Modified treatment algorithms have been proposed for the pandemic. We assessed new algorithms proposed by The European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Acute Cardiovascular Care Association (ACCA) on patients with ACS admitted to the hospital during the COVID-19 pandemic. The COVID-19 period group (CPG) consisted of patients admitted into a high-volume centre in Prague between 1 February 2020 and 30 May 2020 (n = 181). The reference group (RG) included patients who had been admitted between 1 October 2018 and 31 January 2020 (n = 834). The proportions of patients with different types of ACS admitted before and during the pandemic did not differ significantly: in all ACS patients, KILLIP III-IV class was present in 13.9% in RG and in 9.4% of patients in CPG (p = 0.082). In NSTE-ACS patients, the ejection fraction was lower in the CPG than in the RG (44.7% vs. 50.7%, respectively; p < 0.001). The time from symptom onset to first medical contact did not differ between CPG and RG patients in the respective NSTE-ACS and STEMI groups. The time to early invasive treatment in NSTE-ACS patients and the time to reperfusion in STEMI patients were not significantly different between the RG and the CPG. In-hospital mortality did not differ between the groups in NSTE-ACS patients (odds ratio in the CPG 0.853, 95% confidence interval (CI) 0.247 to 2.951; p = 0.960) nor in STEMI patients (odds ratio in CPG 1.248, 95% CI 0.566 to 2.749; p = 0.735). Modified treatment strategies for ACS during the COVID-19 pandemic did not cause treatment delays. Hospital mortality did not differ.
Journal Article
Activated Sludge Respiration Activity Inhibition Caused by Mobile Toilet Chemicals
by
Nováčková, Markéta
,
Kushkevych, Ivan
,
Vítězová, Monika
in
Activated sludge
,
Activated sludge process
,
Antimicrobial agents
2020
Ensuring high quality drinking water sources is important task nowadays. To reach this task, knowledge about the impact of different chemicals on aerobic wastewater treatment is mandatory. A mixture of different chemicals reaches wastewater treatment plant every day. With the growing discharge volume of mobile toilet chemicals, active substances in these products in the past years have been recorded. The respiratory activity of activated sludge was determined to show how mobile toilet chemicals and their active substances may affect the biological wastewater treatment process. The results show negative effect of formaldehyde and bronopol on respiratory activity of activated sludge. The wastewater treatment plants influent composition and size also play important roles. Results shows that activated sludge microorganisms at a wastewater treatment plant in industrial urban area may be adapted to the higher pollutants concentration. When mobile toilet tanks are directly discharged at smaller wastewater treatment plant, an activated sludge process can be affected. For treating mobile toilet wastewater, bacterial degraders can be used. During our respiratory activity experiments, potential degraders were searched. Ralstonia sp. prevails in all samples and it is therefore a potential mobile toilet chemicals degrader.
Journal Article